News AZ is three for three with COPD hope tozorakimab AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.
News Where others missed, AZ's IL-33 drug hits the mark in COPD AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.
News Generate's IPO gets over the line, raising $400m AI-powered drug developer Generate Biomedicine completes a $400m IPO, the largest for biotech on the Nasdaq so far this year.
News COPD patients will get access to Dupixent via NHS Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.
News China clears GSK's Nucala for COPD GSK has unlocked a big new market for Nucala for COPD - China - which accounts for around a quarter of the global patient population.
News GSK closes on approval of asthma hope depemokimab GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.
News Norgine gets first EU approval for WHIM syndrome therapy Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
